• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 26, 2015

View Archived Issues

Amgen scores first in anti-PCSK9 race with EMA nod for Repatha

LONDON – Amgen Inc.'s cardiovascular franchise is cleared for takeoff with Repatha winning the EMA's nod, both as the first of a new class of PCSK9 inhibitors and as the first monoclonal antibody for a cardiovascular indication. Read More

Analysts spin, balance Meniere's data; after near miss, Otonomy heads to phase III

With primary endpoint-missing phase IIb data in hand, Otonomy Inc. CEO David Weber told BioWorld Today that he is "more confident today" that OTO-104 for Meniere's disease is a viable product, and the company will be meeting with the FDA to talk about the planned phase III program. Read More

Chinese consortium snaps up Ambrx to bring new drugs to Chinese patients

A consortium of some of China's biggest health care players is snapping up trans-Pacific protein therapeutics developer Ambrx Inc. for an undisclosed amount in a bid to accelerate the introduction of innovative, and presumably more profitable, therapies to the Chinese market. Read More

New leptin sensitizer leads to elephantine weight loss in rodents

Researchers at Boston Children's Hospital have used a novel type of screening to identify a compound that caused massive weight loss in mice with diet-induced obesity, causing them to lose 45 percent of their body weight. Read More

China channels resources to expand biopharma sector in 25-year plan

HONG KONG – After eyeing biopharmaceuticals as a key area for breakthrough developments, China's State Council has released a roadmap for the manufacturing sector. Read More

Holiday Notice

BioWorld's offices were closed Monday, May 25, in observance of the Memorial Day holiday in the U.S. Read More

Financings

Cel-Sci Corp., of Vienna, Va., priced a best-efforts offering of common stock and warrants at a combined price of 79 cents per unit for gross proceeds of up to $16 million. Read More

Other news to note

Merus Labs International Inc., of Toronto, said one of its wholly owned subsidiaries signed a deal to acquire the rights to manufacture, market and sell two established specialty pharmaceutical products in certain European and other markets. Read More

Stock movers

Read More

In the clinic

Cardiorentis AG, of Zug, Switzerland, completed enrollment in True-AHF, its pivotal phase III trial for the treatment of acute heart failure (AHF), an event-driven trial that enrolled 2,157 patients with AHF. Read More

Appointments and advancements

Armetheon Inc., of Menlo Park, Calif., appointed Andrew C. Lam vice president of product development. Read More

Bench Press: BioWorld looks at translational medicine

Researchers at the University of California at San Francisco have gained new insights into why childhood vaccinations appear to protect not only against the specific infections they were developed against, but also against the development of acute lymphoblastic leukemia, a pediatric B-cell cancer whose incidence has fallen drastically since the advent of routine vaccinations. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe